Médecine

Paramédical

Autres domaines


S'abonner

Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis - 14/12/17

Doi : 10.1016/j.jaad.2017.03.003 
Jacob P. Thyssen, MD, PhD, DMSc a, b, , Peter B. Toft, MD, DMSc c, Anne-Sofie Halling-Overgaard, MS a, Gunnar H. Gislason, MD, PhD d, e, f, Lone Skov, MD, PhD, DMSc a, Alexander Egeberg, MD, PhD a
a Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark 
b National Allergy Research Centre, Gentofte, Denmark 
c Eye Clinic, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark 
d Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark 
e The Danish Heart Foundation, Copenhagen, Denmark 
f National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark 

Reprint requests: Jacob P. Thyssen, MD, PhD, DMSc, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark.

Abstract

Background

Ocular comorbidities are common in atopic dermatitis (AD) as the result of the disease itself or the use of medication. No large-scale epidemiologic data exist on the prevalence of ocular comorbidities in adults with AD.

Objectives

We sought to examine the prevalence and risk of selected ocular comorbidities in adult patients with AD.

Methods

All Danish individuals ≥18 years of age were linked in nationwide registries. Adjusted hazard ratios (HRs) were estimated by means of Cox regression.

Results

A total of 5766 and 4272 adults were categorized as having mild and severe AD, respectively. At least 1 prescription of anti-inflammatory ocular agents was claimed in 12.0% and 18.9% of patients with mild and severe AD, respectively. In adjusted analysis, the HR of conjunctivitis was 1.48 (95% confidence interval [CI], 1.15-1.90) for mild AD and 1.95 (95% CI, 1.51-2.51) for severe AD. The HR of keratitis was 1.66 (95% CI, 1.15-2.40) for mild AD and 3.17 (95% CI, 2.31-4.35) for severe AD. For adults with severe AD, the HR for keratoconus was 10.01 (95% CI, 5.02-19.96). AD was associated with “cataract only” in individuals <50 years of age.

Limitations

A limitation of the study is that observational studies cannot establish causality.

Conclusions

Adults with AD had a significant and disease severity–dependent increased risk of development of conjunctivitis, keratitis, and keratoconus compared with that of the general population.

Le texte complet de cet article est disponible en PDF.

Key words : atopic dermatitis, conjunctivitis, epidemiology, ocular, prevalence, risk

Abbreviations used : AD, AKC, CI, HR, ICD, IL, OR, VKC


Plan


 Dr Thyssen is supported by an unrestricted grant from the Lundbeck Foundation, has attended an advisory board for Roche and Sanofi-Genzyme, and has been a speaker on atopic dermatitis for LEO Pharma. Dr Toft and Anne-Sofie Halling-Overgaard have no conflicts of interest. Dr Gislason is supported by an unrestricted research scholarship from the Novo Nordisk Foundation. Dr Skov has received consultancy and/or speaker honoraria from Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, and Leo Pharma and is a member of the advisory boards of Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, Eli Lilly, Celgene, and Novartis. Dr Egeberg has received research funding from Pfizer and Eli Lilly and honoraria as consultant and/or speaker from Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals.
 Conflicts of interest: The authors have no conflicts of interest to declare.


© 2017  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 77 - N° 2

P. 280 - août 2017 Retour au numéro
Article précédent Article précédent
  • Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey
  • Laurent Eckert, Shaloo Gupta, Caroline Amand, Abhijit Gadkari, Puneet Mahajan, Joel M. Gelfand
| Article suivant Article suivant
  • Real-world burden of comorbidities in US patients with psoriasis
  • Kamal Shah, Lillian Mellars, Arun Changolkar, Steven R. Feldman

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.